Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-863 in Pulmonary Arterial Hypertension
NCT07441200Phase 2Recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NS-863 in pulmonary arterial hypertension (PAH) (3 arms), sponsored by NS Pharma, Inc. Primary endpoints: Pulmonary Vascular Resistance at 24 weeks and Adverse Events at 24 weeks. Started Sep 2026; status: recruiting.
02
Drugs
NS-863
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07441200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441200.